Jack Nicol was initially rejected from the program as co-pilot on The Gudgenby Mission when it was revealed he had a debilitating fear of heights. When no-one was willing to step into the role, a crack team of medical researchers were commissioned to develop a ‘fear of heights medication’, to assist Jack into orbit. The drug was quickly approved for general consumption and has become widely available. It is credited for an explosion in turnover for the Sydney harbour bridge climb company. Space travel and exploration continue to provide spinoff benefits through research and development.